- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.
Moderna and Merck Combination Therapy Meets Primary Endpoint in Melanoma Trial
What happened
Moderna presented Phase 3 results for intismeran, an individualized neoantigen therapy, when combined with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival. Among 1,137 randomized patients, the combination therapy reduced the risk of recurrence or death by 42% versus pembrolizumab alone.
From themarketsdaily.com
Why it matters
The successful trial validates the efficacy of the combination therapy for melanoma. This outcome supports the joint efforts of Moderna and Merck in seeking regulatory review for novel cancer treatments.
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
From themarketsdaily.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.